ReviewNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2013
Phosphate control in end-stage renal disease: barriers and opportunities.
Review in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- The efficacy and safety of cuttlebone for lowering serum phosphate in patients with end-stage renal disease: a meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2023Pooled it
- Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study.Scientific reports · 2019Trial
- Clinical Evaluation of Low-Dose Magnesium Carbonate as a Phosphate Binder in Chronic Hemodialysis Patients.Life (Basel, Switzerland) · 2026Article
- Phosphate-latest news and ongoing trials.Clinical kidney journal · 2026Review
- The Impact of Tenapanor on Serum Phosphate in Adult Dialysis Patients: A Narrative Review.Kidney medicine · 2026Review
- Regulation of Renal and Extrarenal Calcitriol Synthesis and Its Clinical Implications.International journal of molecular sciences · 2025Review
- Construction and validation of a predictive model for the serum phosphorus reduction after total parathyroidectomy in patients with secondary hyperparathyroidism.Frontiers in endocrinology · 2025Article
- Barriers and Facilitators to Adherence to a Healthy Diet Across the Spectrum of Chronic Kidney Disease.Patient preference and adherence · 2025Article
- Removal of calciprotein particles from the blood using an adsorption column improves prognosis of hemodialysis miniature pigs.Scientific reports · 2023Article
- Evaluation of laboratory values affecting mortality of end-stage renal disease patients: a competing risks approach.BMC nephrology · 2023Article
- A real-world analysis of the influence of age on maintenance hemodialysis patients: managing serum phosphorus with sucroferric oxyhydroxide as part of routine clinical care.International urology and nephrology · 2023Article
- Phosphate-Trapping Liposomes for Long-Term Management of Hyperphosphatemia.Materials (Basel, Switzerland) · 2022Article
- Postdialysis serum phosphate equilibrium in hemodialysis patients on a controlled diet and no binders.Hemodialysis international. International Symposium on Home Hemodialysis · 2022Article
- The Impact of Phosphorus Management Today on Quality of Life: Patient Perspectives.Kidney medicine · 2022Article
- Article
- Sociodemographic Factors and Comorbidities Including Hyperparathyroidism Are Associated With an Increased Risk of Band Keratopathy: A Population-Based Study in Taiwan.Frontiers in endocrinology · 2022Article
- αNutrients · 2021Article
- Mediterranean Diet Adherence and Nutritional Status in Dalmatian Kidney Transplant Recipients-Are They Related?Nutrients · 2021Article
- Associated Factors With Uremic Pruritus in Chronic Hemodialysis Patients: A Single-Center Observational Study.Cureus · 2021Article
- Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia.International journal of nephrology and renovascular disease · 2021Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Hyperphosphatemia is a nearly universal complication of end-stage renal disease that is widely recognized as one of the most important and most challenging clinical targets to meet in the care of dialysis patients. Left untreated, it can lead to bone pain, pruritus and worsening secondary hyperparathyroidism. Data from observational studies demonstrate that an elevated serum phosphorus level is an independent risk factor for mortality, and that treatment with phosphate binders is independently associated with improved survival. Experimental studies provide support for the epidemiologic findings: phosphate excess promotes vascular calcification, induces endothelial dysfunction and may contribute to other emerging chronic kidney disease-specific mechanisms of cardiovascular toxicity. On the basis of this evidence, clinical practice guidelines recommend specific targets for serum phosphorus levels in the dialysis population. The purpose of this review is to summarize common challenges in meeting these targets and to identify potential opportunities for improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.